[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

Ryuichi Harada; Nobuyuki Okamura; Shozo Furumoto; Katsutoshi Furukawa; Aiko Ishiki; Naoki Tomita; Kotaro Hiraoka; Shoichi Watanuki; Miho Shidahara; Masayasu Miyake; Yoichi Ishikawa; Rin Matsuda; Akie Inami; Takeo Yoshikawa; Tetsuro Tago; Yoshihito Funaki; Ren Iwata; Manabu Tashiro; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo

doi:10.1007/s00259-015-3035-4

[¹⁸F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

Ryuichi Harada, Nobuyuki Okamura, Shozo Furumoto, Katsutoshi Furukawa, Aiko Ishiki, Naoki Tomita, Kotaro Hiraoka, Shoichi Watanuki, Miho Shidahara, Masayasu Miyake, Yoichi Ishikawa, Rin Matsuda, Akie Inami, Takeo Yoshikawa, Tetsuro Tago, Yoshihito Funaki, Ren Iwata, Manabu Tashiro, Kazuhiko Yanai, Hiroyuki AraiYukitsuka Kudo

Research output: Contribution to journal › Article › peer-review

87 Citations (Scopus)

Abstract

Purpose: Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [¹⁸F]THK-5117 as a highly selective tau imaging radiotracer. Methods: We initially evaluated in vitro binding of [³H]THK-5117 in post-mortem brain tissues from patients with Alzheimer’s disease (AD). In clinical PET studies, [¹⁸F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [¹¹C]PiB PET scan within 2 weeks. Results: In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [¹⁸F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [¹¹C]PiB, [¹⁸F]THK-5117 retention was higher in the medial temporal cortex. Conclusion: These findings suggest that [¹⁸F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.

Original language	English
Pages (from-to)	1052-1061
Number of pages	10
Journal	European journal of nuclear medicine and molecular imaging
Volume	42
Issue number	7
DOIs	https://doi.org/10.1007/s00259-015-3035-4
Publication status	Published - 2015 Jun 1

Keywords

Alzheimer’s disease
Imaging
Neurofibrillary tangles
PET
Tau
[F]THK-5117

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-015-3035-4

Fingerprint Dive into the research topics of '[<sup>18</sup>F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this

Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., Ishikawa, Y., Matsuda, R., Inami, A., Yoshikawa, T., Tago, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., ... Kudo, Y. (2015). [¹⁸F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. European journal of nuclear medicine and molecular imaging, 42(7), 1052-1061. https://doi.org/10.1007/s00259-015-3035-4

[¹⁸F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. / Harada, Ryuichi; Okamura, Nobuyuki; Furumoto, Shozo; Furukawa, Katsutoshi; Ishiki, Aiko ; Tomita, Naoki ; Hiraoka, Kotaro; Watanuki, Shoichi; Shidahara, Miho; Miyake, Masayasu; Ishikawa, Yoichi; Matsuda, Rin; Inami, Akie; Yoshikawa, Takeo; Tago, Tetsuro; Funaki, Yoshihito; Iwata, Ren; Tashiro, Manabu ; Yanai, Kazuhiko ; Arai, Hiroyuki; Kudo, Yukitsuka.

In: European journal of nuclear medicine and molecular imaging, Vol. 42, No. 7, 01.06.2015, p. 1052-1061.

Research output: Contribution to journal › Article › peer-review

Harada, R, Okamura, N, Furumoto, S, Furukawa, K, Ishiki, A , Tomita, N , Hiraoka, K, Watanuki, S, Shidahara, M, Miyake, M, Ishikawa, Y, Matsuda, R, Inami, A, Yoshikawa, T, Tago, T, Funaki, Y, Iwata, R, Tashiro, M , Yanai, K , Arai, H & Kudo, Y 2015, '[¹⁸F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease', European journal of nuclear medicine and molecular imaging, vol. 42, no. 7, pp. 1052-1061. https://doi.org/10.1007/s00259-015-3035-4

Harada, Ryuichi ; Okamura, Nobuyuki ; Furumoto, Shozo ; Furukawa, Katsutoshi ; Ishiki, Aiko ; Tomita, Naoki ; Hiraoka, Kotaro ; Watanuki, Shoichi ; Shidahara, Miho ; Miyake, Masayasu ; Ishikawa, Yoichi ; Matsuda, Rin ; Inami, Akie ; Yoshikawa, Takeo ; Tago, Tetsuro ; Funaki, Yoshihito ; Iwata, Ren ; Tashiro, Manabu ; Yanai, Kazuhiko ; Arai, Hiroyuki ; Kudo, Yukitsuka. / [¹⁸F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. In: European journal of nuclear medicine and molecular imaging. 2015 ; Vol. 42, No. 7. pp. 1052-1061.

@article{f078ea52010a4e0685ce4f8d02ea0078,

title = "[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer{\textquoteright}s disease",

abstract = "Purpose: Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [18F]THK-5117 as a highly selective tau imaging radiotracer. Methods: We initially evaluated in vitro binding of [3H]THK-5117 in post-mortem brain tissues from patients with Alzheimer{\textquoteright}s disease (AD). In clinical PET studies, [18F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [11C]PiB PET scan within 2 weeks. Results: In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [18F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [11C]PiB, [18F]THK-5117 retention was higher in the medial temporal cortex. Conclusion: These findings suggest that [18F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.",

keywords = "Alzheimer{\textquoteright}s disease, Imaging, Neurofibrillary tangles, PET, Tau, [F]THK-5117",

author = "Ryuichi Harada and Nobuyuki Okamura and Shozo Furumoto and Katsutoshi Furukawa and Aiko Ishiki and Naoki Tomita and Kotaro Hiraoka and Shoichi Watanuki and Miho Shidahara and Masayasu Miyake and Yoichi Ishikawa and Rin Matsuda and Akie Inami and Takeo Yoshikawa and Tetsuro Tago and Yoshihito Funaki and Ren Iwata and Manabu Tashiro and Kazuhiko Yanai and Hiroyuki Arai and Yukitsuka Kudo",

year = "2015",

month = jun,

day = "1",

doi = "10.1007/s00259-015-3035-4",

language = "English",

volume = "42",

pages = "1052--1061",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "7",

}

TY - JOUR

T1 - [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

AU - Harada, Ryuichi

AU - Okamura, Nobuyuki

AU - Furumoto, Shozo

AU - Furukawa, Katsutoshi

AU - Ishiki, Aiko

AU - Tomita, Naoki

AU - Hiraoka, Kotaro

AU - Watanuki, Shoichi

AU - Shidahara, Miho

AU - Miyake, Masayasu

AU - Ishikawa, Yoichi

AU - Matsuda, Rin

AU - Inami, Akie

AU - Yoshikawa, Takeo

AU - Tago, Tetsuro

AU - Funaki, Yoshihito

AU - Iwata, Ren

AU - Tashiro, Manabu

AU - Yanai, Kazuhiko

AU - Arai, Hiroyuki

AU - Kudo, Yukitsuka

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Purpose: Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [18F]THK-5117 as a highly selective tau imaging radiotracer. Methods: We initially evaluated in vitro binding of [3H]THK-5117 in post-mortem brain tissues from patients with Alzheimer’s disease (AD). In clinical PET studies, [18F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [11C]PiB PET scan within 2 weeks. Results: In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [18F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [11C]PiB, [18F]THK-5117 retention was higher in the medial temporal cortex. Conclusion: These findings suggest that [18F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.

AB - Purpose: Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [18F]THK-5117 as a highly selective tau imaging radiotracer. Methods: We initially evaluated in vitro binding of [3H]THK-5117 in post-mortem brain tissues from patients with Alzheimer’s disease (AD). In clinical PET studies, [18F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [11C]PiB PET scan within 2 weeks. Results: In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [18F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [11C]PiB, [18F]THK-5117 retention was higher in the medial temporal cortex. Conclusion: These findings suggest that [18F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.

KW - Alzheimer’s disease

KW - Imaging

KW - Neurofibrillary tangles

KW - PET

KW - Tau

KW - [F]THK-5117

UR - http://www.scopus.com/inward/record.url?scp=84938996337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938996337&partnerID=8YFLogxK

U2 - 10.1007/s00259-015-3035-4

DO - 10.1007/s00259-015-3035-4

M3 - Article

C2 - 25792456

AN - SCOPUS:84938996337

VL - 42

SP - 1052

EP - 1061

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 7

ER -